Regeneus CEO John Martin Talks About The Licensing Of Progenza In Japan

Licensing Deal with AGC in Japan means rapid growth

Sydney, Mar 9, 2017 - (ABN Newswire) - Regeneus Ltd (ASX:RGS) is an Australian clinical-stage regenerative medicine company developing a portfolio of innovative cellular therapies targeting significant unmet medical needs in both human and animal health markets.

With the recent announcement of a significant licensing deal with AGC Ltd in Japan, the company is set to build on their platform for the delivery of Progenza to deal with many healthcare issues from arthritis and pain, to genetic disorders.

The Japanese deal means the company is moving quickly into a new stage of growth as explained by CEO John Martin in a video interview.

To view the video interview, please visit:

About: Regeneus Ltd

Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases.

Back to news